Integrity Continuing Education: Podcast Series: Recent Episodes
Integrity CE
Our mission is to develop and implement cutting-edge CME/CE initiatives featuring evidence-based scientific content of the highest integrity.
In this next episode of the series, experts George L. Bakris, MD and Biff F. Palmer, MD take another stab at the health implications of HK in patients with ESRD and the available strategies for optimizing management. Listen closely as they discuss the challenges in HK identification, the key causes of HK, the importance of appropriate monitoring, & more!
For additional information and to claim credit visit,
https://integrityce.com/hkpodcast2
View the figures referenced during this podcast episode here:
https://integrityce.com/wp-content/uploads/2021/12/i785_podcast-2-figures-2.pdf
Integrity Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Supported by an educational grant from AstraZeneca Pharmaceuticals LP.
Listen to the first episode of this podcast series at,
https://integrityce.com/courses/updates-evolving-care-considerations-in-the-mitigation-of-hyperkalemia-in-patients-with-end-stage-renal-disease-on-dialysis/
In the first podcast of this series Nephrology experts Christos Argyropoulos, MD, PhD, FASN and Edgar Lerma, MD discussed the development and use of mineralocorticoid antagonists for the treatment of chronic kidney disease (CKD). In this next episode, they further that discussion by diving into the burdens and complex pathophysiology of CKD, followed by the complexities and considerations for screening and diagnosis. They then close out the conversation with a brief review of the emerging non-steroidal mineralocorticoid antagonists for CKD.
For more information and to claim credit visit, https://integrityce.com/ckdpodcast2
View the figures referenced during this podcast here: https://integrityce.com/wp-content/uploads/2021/11/i782-8_podcast-2_figures.pdf
Integrity Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc.
You can listen the first episode of this podcast at, https://integrityce.com/ckdpodcast1
Though rare in the general population, hyperkalemia often occurs among patients with CKD, particularly among older individuals in advanced stages of the disease. Patients with hyperkalemia are predisposed to cardiac hyperexcitability & depression, both of which can be fatal, particularly if not treated rapidly. This educational activity will provide a review of hyperkalemia, including a discussion of the associated health burden, risk factors, & evidence-based management strategies. In addition, recent FDA approvals & clinical trial data supporting improved outcomes in high-risk patients will also be considered.
Patients with CKD and anemia experience substantially increased burdens to morbidity and mortality. The use of erythropoiesis-stimulating agent (ESA) and iron supplementation are mainstays of therapy, yet ESA has been associated with increased cardiovascular adverse events. Furthermore, some patients are resistant to ESA, resulting in higher doses to reach target hemoglobin levels and increasing the risk of adverse events. Increased understanding of hypoxia-inducible factors (HIFs) have led to the development of novel therapies, HIF-PHIs, that work by simulating hypoxia in cells, thereby stimulating EPO synthesis and improving iron metabolism and mobilization through reduced hepcidin levels. Three HIF-PHIs (i.e. roxadustat, vadadustat, and daprodustat) are currently undergoing or have recently completed late-stage development. To be best prepared to incorporate these agents into clinical practice once FDA-approved, nephrologists must be educated on the burdens associated with anemia in CKD, pathophysiological mechanisms involved in CKD-related anemia, and recent outcomes from clinical trials evaluating HIF-PHIs in patients with CKD. This educational activity will address these knowledge gaps among nephrologists, and application of this knowledge will improve outcomes for patients with anemia and CKD.
Earn Credit/ Learning Objectives and Disclosures
https://bit.ly/3fPj151
Integrity Continuing Education designates this podcast for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an educational grant from AstraZeneca Pharmaceuticals LP in collaboration with FibroGen.
Although much remains unknown about coronavirus disease 2019 (COVID-19), knowledge is expanding every hour, and many healthcare providers, overwhelmed by infected patients and a struggling healthcare infrastructure, are unable to keep up with the changing landscape. Furthermore, the lag in peer-reviewed publication timelines means that the most critical information, when not disseminated by the Centers for Disease Control and Prevention (CDC) or national and international organizations, will be distributed by mainstream media through social media platforms, interspersed with false, contradictory, or misleading information, thereby presenting additional time-consuming challenges to clinicians. The rapidly evolving nature of the pandemic necessitates the dissemination of up-to-date information through continuing education programs in order to ensure healthcare providers are optimally prepared to care for patients.
With cases of COVID-19 surpassing 51 million worldwide, the rush to develop a vaccine capable of slowing the pandemic and lessening the morbidity and mortality of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is underway. Several COVID-19 vaccines are now being studied in phase 3 trials, and clinicians would benefit from a review of these ongoing efforts, particularly the status of vaccines authorized or close to authorization. This educational activity will provide clinicians a review of up-to-date safety and efficacy information on vaccine candidates in late-stage development.
View CME information & earn credit: https://bit.ly/3o5X7hR
Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.
Chronic kidney disease (CKD) in a complex disorder. Overactivation of the mineralocorticoid receptor plays a substantial role, with binding of aldosterone causing inflammation and fibrosis that leads to kidney disfunction. Targeting the mineralocorticoid receptor by blocking aldosterone was first explored in the 1930s, and in 1960, the first mineralocorticoid receptor antagonist, spironolactone, was introduced. The first of these agents were steroidal agents, and while they are still widely prescribed, they are associated with a number of adverse effects that limit their use. This prompted the search for nonsteroidal agents that target the mineralocorticoid receptor. Three agents (apararenone, esaxerenone, and finerenone) are furthest along in development. Nephrologists involved in the care of patients with CKD should be informed about the efficacy and safety profiles of these agents in order to be prepared for their potential approval by the US FDA. This educational activity will address this knowledge gap by providing a summary of the evolution of this class of agents and an overview of the phase 3 clinical data of the nonsteroidal agents, so that clinicians are able to provide optimal care for their patients with CKD.
Earn Credit/ Learning Objectives and Disclosures
https://integrityce.com/ckdpodcast1
Integrity Continuing Education designates this podcast for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc.
Experts discuss how to be best prepared to incorporate these agents into clinical practice once FDA-approved, nephrologists must be educated on the burdens associated with anemia in CKD, pathophysiological mechanisms involved in CKD-related anemia, and recent outcomes from clinical trials evaluating HIF-PHIs in patients with CKD. This educational activity will address these knowledge gaps among nephrologists, and application of this knowledge will improve outcomes for patients with anemia and CKD.
Earn Credit/ Learning Objectives and Disclosures
https://integrityce.com/ckdanemiapodcast1
Integrity Continuing Education designates this podcast for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an educational grant from AstraZeneca Pharmaceuticals LP in collaboration with FibroGen.